iCAD Touts PMA-Approved Tool As Time-Saver For 3D Breast Assessment

iCAD won US FDA approval for its PowerLook Tomo Detection computer-aided detection tool for the growing field of digital breast 3D tomosynthesis product. It's intended to address a key complaint by radiologists with tomosynthesis: the long time it takes to read 3D, compared to 2D exams.

US FDA approved iCAD Inc.'s PMA for its PowerLook Tomo Detection solution for breast tumor detection March 24. The firm says the product is the first ever concurrent-read computer aided detection (CAD) solution for digital breast tomosynthesis (DBT).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Oncology

MedStar Teams Up With Reimagine Care To Extend Cancer Care Into Patients’ Home

 
• By 

Reimagine Care teamed up with MedStar Health to support cancer patients at home via an AI assistant and clinical support. Reimagine Care’s data suggests its platform can save cancer centers up to $1m annually per full-time oncologist panel and reduce ED visits by 30%.

Exact Sciences Launches Cologuard Plus

 

The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.

Wired Health: ‘Early Diagnosis Often Benefits Science But Not The Patient’

 

Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.

LSI 2025: Intuitive Surgical CEO Gary Guthart On da Vinci 5’s Force Feedback, Digital Coaching, ION Expansion, And Robotic Surgery’s Future

 
• By 

Medtech Insight sat down with Intuitive Surgical CEO Gary Guthart at the recent LSI USA conference to discuss the full launch of the new da Vinci 5 robotic system and planned digital enhancements. Guthart also offered his views on health care interoperability, AI regulation, outpatient surgeries, autonomous robots, and how the company is harnessing technology to shape the future of robotic surgery.

More from Device Area

Looking Back Towards The Future

 

As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.

J&J Medtech’s FDA-Cleared DUALTO System Prepares For Future Use With OTTAVA Robotic Platform

 
• By 

DUALTO’s double-module option provides enhanced flexibility while cutting down on equipment clutter. Compared to traditional setups, the system reduces OR footprint by 46%, helping staff reclaim space and optimize surgical workflows.

Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

 

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.